JP MORGAN/CALL/BOSTON SCIENTIFIC/78/0.1/15.11.24 | Real-time Bid/Ask 03:00:04 2024-06-20 EDT | ||
| 0.67 EUR / 0.7 EUR | +3.79% |
|
| 1 month | +1.54% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BOSTON SCIENTIFIC CORPORATION
| Date | Price | Change |
|---|---|---|
| 24-06-19 | 0.66 | +1.54% |
| 24-06-18 | 0.65 | -12.16% |
| 24-06-17 | 0.74 | +7.25% |
| 24-06-14 | 0.69 | -5.48% |
| 24-06-13 | 0.73 | -1.35% |
Delayed Quote Börse Stuttgart
Last update June 19, 2024 at 06:08 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | BOSTON SCIENTIFIC CORPORATION |
| Issuer | J.P. Morgan |
| WKN | JK7G74 |
| ISIN | DE000JK7G745 |
| Date issued | 2024-04-02 |
| Strike | 78 $ |
| Maturity | 2024-11-15 (149 Days) |
| Parity | 10 : 1 |
| Emission price | 0.24 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.78 € |
|---|---|
| Lowest since issue | 0.4 € |
| Spread | 0.03 € |
| Spread % | 4.29% |
Company Profile
Boston Scientific Corporation specializes in the design, manufacturing and marketing of medical equipment and materials. Net sales break down by area of application as follows:
- cardiovascular (60.6%): products used in cardiology surgeries (27.4% of net sales), cardiac rhythm management (25.2%), peripheral surgeries (23.9%), electrophysiology tests (9.1%) and other (14.4%);
- endodontic surgery (37.4%): equipment used in endoscopy (45.8% of net sales), urology (36.2%) and other (18%) ;
- neuromodulation (2%).
The United States account for 59.2% of net sales.
Sector
-
Ratings for Boston Scientific Corporation
Trading Rating
Investor Rating
ESG Refinitiv
A-
Consensus: Boston Scientific Corporation
Sell
Buy
Mean consensus
BUY
Number of Analysts
31
Last Close Price
76.31
USD
Average target price
82
USD
Spread / Average Target
+7.45%
- Stock Market
- Warrants
- Warrant
